Pfizer SG&A Expenses 2012-2026 | PFE
Pfizer annual/quarterly sg&a expenses history and growth rate from 2012 to 2026. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Pfizer sg&a expenses for the quarter ending March 31, 2026 were $2.961B, a 2.31% decline year-over-year.
- Pfizer sg&a expenses for the twelve months ending March 31, 2026 were $13.724B, a 3.8% decline year-over-year.
- Pfizer annual sg&a expenses for 2025 were $13.794B, a 6.35% decline from 2024.
- Pfizer annual sg&a expenses for 2024 were $14.73B, a 0.28% decline from 2023.
- Pfizer annual sg&a expenses for 2023 were $14.771B, a 8% increase from 2022.
|
Pfizer Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025 | $13,794 |
| 2024 | $14,730 |
| 2023 | $14,771 |
| 2022 | $13,677 |
| 2021 | $12,703 |
| 2020 | $11,597 |
| 2019 | $12,726 |
| 2018 | $12,612 |
| 2017 | $14,804 |
| 2016 | $14,844 |
| 2015 | $14,809 |
| 2014 | $14,097 |
| 2013 | $14,355 |
| 2012 | $15,171 |
| 2011 | $17,581 |
|
Pfizer Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,961 |
| 2025-12-31 | $4,162 |
| 2025-09-30 | $3,186 |
| 2025-06-30 | $3,415 |
| 2025-03-31 | $3,031 |
| 2024-12-31 | $4,274 |
| 2024-09-30 | $3,244 |
| 2024-06-30 | $3,717 |
| 2024-03-31 | $3,495 |
| 2023-12-31 | $4,575 |
| 2023-09-30 | $3,281 |
| 2023-06-30 | $3,497 |
| 2023-03-31 | $3,418 |
| 2022-12-31 | $4,645 |
| 2022-09-30 | $3,391 |
| 2022-06-30 | $3,048 |
| 2022-03-31 | $2,593 |
| 2021-12-31 | $4,104 |
| 2021-09-30 | $2,899 |
| 2021-06-30 | $2,923 |
| 2021-03-31 | $2,777 |
| 2020-12-31 | $3,739 |
| 2020-09-30 | $2,658 |
| 2020-06-30 | $2,659 |
| 2020-03-31 | $2,541 |
| 2019-12-31 | $2,616 |
| 2019-09-30 | $3,260 |
| 2019-06-30 | $3,511 |
| 2019-03-31 | $3,339 |
| 2018-12-31 | $2,164 |
| 2018-09-30 | $3,494 |
| 2018-06-30 | $3,542 |
| 2018-03-31 | $3,412 |
| 2017-12-31 | $4,555 |
| 2017-09-30 | $3,504 |
| 2017-06-30 | $3,430 |
| 2017-03-31 | $3,315 |
| 2016-12-31 | $4,429 |
| 2016-09-30 | $3,559 |
| 2016-06-30 | $3,471 |
| 2016-03-31 | $3,385 |
| 2015-12-31 | $5,049 |
| 2015-09-30 | $3,270 |
| 2015-06-30 | $3,386 |
| 2015-03-31 | $3,104 |
| 2014-12-31 | $3,981 |
| 2014-09-30 | $3,556 |
| 2014-06-30 | $3,520 |
| 2014-03-31 | $3,040 |
| 2013-12-31 | $4,152 |
| 2013-09-30 | $3,395 |
| 2013-06-30 | $3,591 |
| 2013-03-31 | $3,217 |
| 2012-12-31 | $4,047 |
| 2012-09-30 | $3,491 |
| 2012-06-30 | $3,665 |
| 2012-03-31 | $3,968 |
| 2011-12-31 | $3,821 |
| 2011-09-30 | $4,457 |
| 2011-06-30 | $4,800 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |